产品
编 号：F534686
分子式：C36H45NO7
分子量：603.75
分子式：C36H45NO7
分子量：603.75
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
396
In-stock
10mg
648
In-stock
25mg
1296
In-stock
50mg
2088
In-stock
100mg
3528
In-stock
结构图
CAS No: 94749-08-3
产品详情
生物活性：
Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
体内研究：
Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD).Animal Model:Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g)
Dosage:Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg)
Administration:The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period.
Result:COPD assessment test scores were markedly improved in mice with COPD.
体外研究：
Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation.
Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
体内研究：
Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD).Animal Model:Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g)
Dosage:Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg)
Administration:The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period.
Result:COPD assessment test scores were markedly improved in mice with COPD.
体外研究：
Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备